The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Insights into the potential value of epcoritamab in third-line DLBCL & FL
Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, comments on the value of epcoritamab in treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the third-line setting, highlighting the potential of this agent to achieve high overall response rates and complete remission rates. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
